When comparing two glioblastoma CSC lines, CD133 + and CD133–, it was found that CD133 + cells have increased expression of the MDR1 gene (multiple drug resistance gene 1) and miR-9, which activates Shh signaling by decreasing the PTCH1 level. This evidence concerns the gene PROM1 and glioblastoma.